Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZYFLO CR

« Back to Dashboard
Zyflo Cr is a drug marketed by Chiesi Usa Inc and is included in one NDA. It is available from one supplier.

The generic ingredient in ZYFLO CR is zileuton. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the zileuton profile page.

Summary for Tradename: ZYFLO CR

Suppliers / Packagers: see list2

Pharmacology for Tradename: ZYFLO CR

Clinical Trials for: ZYFLO CR

Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Status: Recruiting Condition: Chronic Myelogenous Leukemia

Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
Status: Completed Condition: Tobacco Use Disorder

Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers
Status: Not yet recruiting Condition: Lung Carcinoma; Tobacco Use Disorder

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
Status: Terminated Condition: Chronic Myelogenous Leukemia

Trial of Zileuton CR in Children and Adults With Sickle Cell Disease
Status: Completed Condition: Sickle Cell Disease

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS
Status: Terminated Condition: Asthma

Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients
Status: Completed Condition: Asthma

Zileuton and Exhaled Nitric Oxide in Asthmatics
Status: Completed Condition: Asthma

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)
Status: Terminated Condition: Pulmonary Disease, Chronic Obstructive

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging
Status: Completed Condition: Lung Inflammation

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc
TABLET, EXTENDED RELEASE;ORAL022052-001May 30, 2007RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn